Jazz Pharmaceuticals
JAZZ
502 hedge funds and large institutions have $6.57B invested in Jazz Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 189 increasing their positions, 179 reducing their positions, and 103 closing their positions.
736% more call options, than puts
Call options by funds: $69.8M | Put options by funds: $8.34M
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
3.43% more ownership
Funds ownership: 98.8% → 102.22% (+3.4%)
6% more repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 179
9% less funds holding
Funds holding: 551 → 502 (-49)
12% less capital invested
Capital invested by funds: $7.45B → $6.57B (-$881M)
43% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 103
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$130M |
| 2 |
Millennium Management
New York
|
+$69.5M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$67M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$48.9M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$33.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$32.5M |
| 2 |
BA
Bridgewater Associates
Westport,
Connecticut
|
-$31.2M |
| 3 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$29.8M |
| 4 |
PCM
Polaris Capital Management
Boston,
Massachusetts
|
-$26.6M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$23.9M |
JAZZ Hedge Fund Activity: Q2 2025 in Review
502 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2025, worth a combined $6.57B — down 12% from $7.45B a quarter earlier.
Sellers outnumbered buyers: 103 funds closed out of JAZZ and 59 opened new positions — a net loss of 44 holders — while 179 trimmed existing stakes and 189 added.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $130M. The largest seller was Two Sigma Investments, cutting an estimated $32.5M.
- 502 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2025, down from 551 in Q1 2025.
- Funds reported $6.57B of Jazz Pharmaceuticals stock for Q2 2025, down 12% quarter-over-quarter.
- 59 funds opened new Jazz Pharmaceuticals positions in Q2 2025 and 103 closed out, a net change of -44 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2025 was Vestal Point Capital, an estimated $130M added.
- The largest Jazz Pharmaceuticals seller in Q2 2025 was Two Sigma Investments, an estimated $32.5M sold.
Based on aggregated 13F filings for Q2 2025.